Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Earnings for Third Harmonic Bio, Inc. (THRD)
Earnings in 2023 (TTM): $-30,824,000
According to Third Harmonic Bio, Inc.'s latest financial reports the company's current earnings (TTM) are $-30,824,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Third Harmonic Bio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-30,824,000 | $-30,824,000 |
| 2022 | $-35,155,000 | $-37,708,000 |
| 2021 | $-29,609,000 | $-29,609,000 |
| 2020 | $-12,808,000 | $-12,807,000 |